XL518
|
- $49 - $8316
- Product name: XL518
- CAS: 934660-93-2
- MF: C21H21F3IN3O2
- MW: 531.31
- EINECS:
- MDL Number:MFCD22124461
- Synonyms:XL518;GDC-0973;RG7420;[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]Methanone;GDC-0973(XL-518);(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)Methanone;XL518 ,GDC-0973;CobiMetinib
21 prices
Selected condition：
Brand
- AK Scientific
- ApexBio Technology
- Biosynth Carbosynth
- Cayman Chemical
- ChemScene
- Crysdot
- DC Chemicals
- Matrix Scientific
- TRC
- Usbiological
Package
- 1mg
- 5mg
- 10mg
- 25mg
- 50mg
- 1g
- 10mM(in 1mL DMSO)
- 100mg
- ManufacturerAK Scientific
- Product number3556AH
- Product descriptionCobimetinib
- Packaging1g
- Price$2398
- Updated2021-12-16
- Buy
- ManufacturerApexBio Technology
- Product numberA3321
- Product descriptionCobimetinib
- Packaging10mM(in 1mL DMSO)
- Price$210
- Updated2021-12-16
- Buy
- ManufacturerApexBio Technology
- Product numberA3321
- Product descriptionCobimetinib
- Packaging50mg
- Price$630
- Updated2021-12-16
- Buy
- ManufacturerBiosynth Carbosynth
- Product numberFD28742
- Product descriptionCobimetinib
- Packaging10mg
- Price$125
- Updated2021-12-16
- Buy
- ManufacturerBiosynth Carbosynth
- Product numberFD28742
- Product descriptionCobimetinib
- Packaging50mg
- Price$437.5
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number19563
- Product descriptionCobimetinib ≥98%
- Packaging1mg
- Price$49
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number19563
- Product descriptionCobimetinib ≥98%
- Packaging5mg
- Price$179
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number19563
- Product descriptionCobimetinib ≥98%
- Packaging10mg
- Price$333
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number19563
- Product descriptionCobimetinib ≥98%
- Packaging25mg
- Price$711
- Updated2024-03-01
- Buy
- ManufacturerChemScene
- Product numberCS-0521
- Product descriptionCobimetinib 99.71%
- Packaging5mg
- Price$96
- Updated2021-12-16
- Buy
- ManufacturerChemScene
- Product numberCS-0521
- Product descriptionCobimetinib 99.71%
- Packaging10mg
- Price$120
- Updated2021-12-16
- Buy
- ManufacturerChemScene
- Product numberCS-0521
- Product descriptionCobimetinib 99.71%
- Packaging50mg
- Price$396
- Updated2021-12-16
- Buy
- ManufacturerChemScene
- Product numberCS-0521
- Product descriptionCobimetinib 99.71%
- Packaging100mg
- Price$576
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31000193
- Product descriptionCobimetinib 98+%
- Packaging10mg
- Price$247
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31000193
- Product descriptionCobimetinib 98+%
- Packaging25mg
- Price$403
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31000193
- Product descriptionCobimetinib 98+%
- Packaging50mg
- Price$605
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 3556AH | Cobimetinib | 1g | $2398 | 2021-12-16 | Buy |
| ApexBio Technology | A3321 | Cobimetinib | 10mM(in 1mL DMSO) | $210 | 2021-12-16 | Buy |
| ApexBio Technology | A3321 | Cobimetinib | 50mg | $630 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FD28742 | Cobimetinib | 10mg | $125 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FD28742 | Cobimetinib | 50mg | $437.5 | 2021-12-16 | Buy |
| Cayman Chemical | 19563 | Cobimetinib ≥98% | 1mg | $49 | 2024-03-01 | Buy |
| Cayman Chemical | 19563 | Cobimetinib ≥98% | 5mg | $179 | 2024-03-01 | Buy |
| Cayman Chemical | 19563 | Cobimetinib ≥98% | 10mg | $333 | 2024-03-01 | Buy |
| Cayman Chemical | 19563 | Cobimetinib ≥98% | 25mg | $711 | 2024-03-01 | Buy |
| ChemScene | CS-0521 | Cobimetinib 99.71% | 5mg | $96 | 2021-12-16 | Buy |
| ChemScene | CS-0521 | Cobimetinib 99.71% | 10mg | $120 | 2021-12-16 | Buy |
| ChemScene | CS-0521 | Cobimetinib 99.71% | 50mg | $396 | 2021-12-16 | Buy |
| ChemScene | CS-0521 | Cobimetinib 99.71% | 100mg | $576 | 2021-12-16 | Buy |
| Crysdot | CD31000193 | Cobimetinib 98+% | 10mg | $247 | 2021-12-16 | Buy |
| Crysdot | CD31000193 | Cobimetinib 98+% | 25mg | $403 | 2021-12-16 | Buy |
| Crysdot | CD31000193 | Cobimetinib 98+% | 50mg | $605 | 2021-12-16 | Buy |
Properties
Melting point :165 - 166°C
Boiling point :565.9±50.0 °C(Predicted)
Density :1.706
storage temp. :Refrigerator
solubility :Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
form :Solid
pka :13.13±0.20(Predicted)
color :Off-White
InChIKey :BSMCAPRUBJMWDF-KRWDZBQOSA-N
SMILES :C(C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F)(N1CC(O)([C@@H]2CCCCN2)C1)=O
Boiling point :565.9±50.0 °C(Predicted)
Density :1.706
storage temp. :Refrigerator
solubility :Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
form :Solid
pka :13.13±0.20(Predicted)
color :Off-White
InChIKey :BSMCAPRUBJMWDF-KRWDZBQOSA-N
SMILES :C(C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F)(N1CC(O)([C@@H]2CCCCN2)C1)=O
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
Cobimetinib, codeveloped by Genentech and Exelixis, was approved in August 2015 in Switzerland and November 2015 in the U.S. and Europe for the treatment of unresectable or metastatic BRAFV600 mutationpositive melanoma when used in combination with vemurafenib. Cobimetinib is a potent, highly selective reversible inhibitor of mitogen-activated protein kinases (MEK) 1 and 2,120 which serves to inhibit phosphorylation of ERK1/2,121 disrupting the MAPK pathway which is responsible for cell proliferation, cell survival, and migration.122 Combination of cobimetinib with vemurafenib, an important BRAF inhibitor,123 enables targeting of multiple points on the MAPK pathway, leading to overall enhanced tumor cell apoptosis and response as compared to stand-alone treatment with vemurafenib.124 Specifically, in a representative trial of previously untreated patients with BRAFV600 mutation-positive, unresectable, stage IIIc or IV melanoma, combination of these two therapies led to a significantly improved progression-free survival and overall response rate versus patients treated only with vemurafenib.Related product price
- Ribonucleic acid
$79-1670 - Capecitabine
$5-1504.5 - Lenvatinib
$5-1410
